
    
      The study will collect safety and efficacy data from pediatric patients who are prescribed
      intravenous micafungin for prophylaxis. During this trial, patients with two separate
      indications will be treated. The first, Invasive candidiasis will have a minimum treatment of
      2 weeks. The second, Oesophageal candidiasis will have a minimum treatment of 1 week. Both
      indications will have a follow-up period of 4 weeks after treatment.
    
  